Role of the Interaction Between Advanced Glycation End Products and Their Receptor RAGE in the Development and the Progression of the Uremic Vasculopathy of Hemodialyzed Patients

Hemodialyzed Patients Clinical Trial

— RAGE-VASCU  

Official title:

Role of the Interaction Between AGEs and Their Receptor RAGE in the Development and the Progression of the Uremic Vasculopathy of Hemodialyzed Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02818465
• Other study ID #: PR14037
• Status: Completed
• Phase: N/A
• First received: June 23, 2016
• Last updated: April 18, 2018
• Start date: March 30, 2015
• Est. completion date: November 16, 2017

Study information

• Verified date: April 2018
• Source: CHU de Reims
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Chronic kidney disease (CKD) is associated with an extensive vasculopathy and high cardiovascular mortality as well as an accumulation of uremic toxins. Among the latest, advanced glycation end-products (AGEs) interact with RAGE. Investigators aimed to analyze the role of RAGE in the calcification process of hemodialyzed patients, in a correlative and prospective study. Vascular calcifications will be assessed by Xray and tomodentimetry while accumulation of AGEs will be measured in the serum and in the skin (non invasive). Additionally factors influencing RAGE activation such as genetic polymorphism and level of soluble forms of RAGE will be measured and analyzed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: November 16, 2017
• Est. primary completion date: November 16, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Renal impairment

• Hemodialysis for more than 3 months

• Have agreed to participate in research

• Affiliated to a social security scheme

• major

Exclusion Criteria:

• Diabetes , for diabetes induces accelerated formation of advanced glycation end products , which could then be a confounding factor in our study.

• Protected by law .

• minors

• pregnant women

• Matt or pigmented skin because the skin hyperpigmentation interfere with reading the skin fluorescence giving falsely elevated values .

• Having an aneurysm of the abdominal aorta known

• Suffering from a progressive neoplastic disease

Related Conditions & MeSH terms

• Hemodialyzed Patients
• Vascular Diseases

Intervention

Other:
• Vascular calcifications by Xray

• Vascular calcifications by tomodentimetry

Biological:
• Blood sample withdrawn

Locations

Country	Name	City	State
France	Chu de Reims	Reims

Sponsors (1)

Lead Sponsor	Collaborator
CHU de Reims

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frammingham Score		up to 12 months